A Phase 4 interventional study of Placebos and Triamcinolone Acetonide 2.5 mg/mL in Nail Psoriasis and Nail Diseases, sponsored by Weill Medical College of Cornell University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-27.
Sponsored by Weill Medical College of Cornell University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This purpose of this study is to determine the lowest effective concentration of intralesional triamcinolone acetonide in the treatment of nail psoriasis.
Weill Medical College of Cornell University is the lead sponsor of 892 studies on the registry; 165 are open to participants now.
Of its 123 completed or terminated interventional studies of FDA-regulated products, 94 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive an intralesional injection of 0.1-0.2 mL of normal saline in one psoriatic fingernail once per 6 weeks until 24 weeks.
Drug: Placebos
Participants receive an intralesional injection of 0.1-0.2 mL of 2.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
Drug: Triamcinolone Acetonide 2.5 mg/mL
Participants receive an intralesional injection of 0.1-0.2 mL of 5.0 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
Drug: Triamcinolone Acetonide 5.0 mg/mL
Participants receive an intralesional injection of 0.1-0.2 mL of 7.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
Drug: Triamcinolone Acetonide 7.5 mg/mL
Participants receive an intralesional injection of 0.1-0.2 mL of 10 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.
Drug: Triamcinolone Acetonide 10 mg/mL
Normal saline intralesional injection
Also known as: Saline solution for injection
Drug page: Triamcinolone Acetonide
2.5 mg/mL intralesional injection
Also known as: Triamcinolone Injection, Kenalog 10 MG/ML Injectable Suspension
Drug page: Triamcinolone Acetonide
5.0 mg/mL intralesional injection
Also known as: Triamcinolone Injection, Kenalog 10 MG/ML Injectable Suspension
Drug page: Triamcinolone Acetonide
7.5 mg/mL intralesional injection
Also known as: Triamcinolone Injection, Kenalog 10 MG/ML Injectable Suspension
Drug page: Triamcinolone Acetonide
10 mg/mL intralesional injection
Also known as: Triamcinolone Injection, Kenalog 10 MG/ML Injectable Suspension
Lowest Effective Concentration of Intralesional Triamcinolone Acetonide for Nail Psoriasis
The most effective concentration of intralesional triamcinolone acetonide will be determined between 0 mg/mL, 2.5 mg/mL, 5.0 mg/mL, 7.5 mg/mL, and 10.0 mg/mL.
Time frame: 24 weeks (end of study)
Change From Baseline in Nail Psoriasis, as Measured by Nail Psoriasis Severity Index (NAPSI)
The Nail Psoriasis Severity Index (NAPSI) is used to evaluate nail psoriasis. Scores range from 0 to 8 with 0 indicating no nail psoriasis and higher scores indicating worsening nail psoriasis.
Time frame: Baseline, 24 weeks (end of study)
Change From Baseline in Nail Psoriasis Qualify of Life, as Measured by Development and Validation of Nail Psoriasis Quality of Life Scale (NPQ10)
The NPQ10 comprises 10 questions gauging the impact of nail psoriasis on daily activities. Each response is scored from 0 to 2, resulting in a total score between 0 and 20, where higher values indicate a more significant impact. The final scores are converted to percentages, reflecting the proportion of questions answered by the patient. The obtained score correlates proportionally with the level of functional difficulty experienced, with 0% indicating no impairment and 100% indicating the worst possible impairment.
Time frame: Baseline, 24 weeks (end of study)
Number of Participants With at Least One Adverse Event
Adverse events will only include those that are determined to be related to the study drug.
Time frame: 24 weeks (end of study)
Participants were recruited from one location in the United States
| Milestone | Placebo | Triamcinolone Acetonide 2.5 mg/mL | Triamcinolone Acetonide 5.0 mg/mL | Triamcinolone Acetonide 7.5 mg/mL | Triamcinolone Acetonide 10 mg/mL |
|---|---|---|---|---|---|
| Started | 11 | 11 | 11 | 11 | 11 |
| Completed | 10 | 10 | 10 | 10 | 10 |
| Not completed | 1 | 1 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 1 | 1 |
The most effective concentration of intralesional triamcinolone acetonide will be determined between 0 mg/mL, 2.5 mg/mL, 5.0 mg/mL, 7.5 mg/mL, and 10.0 mg/mL.
| mg/mL | All Groups |
|---|---|
| Lowest Effective Concentration of Intralesional Triamcinolone Acetonide for Nail Psoriasis | 2.5 |
The Nail Psoriasis Severity Index (NAPSI) is used to evaluate nail psoriasis. Scores range from 0 to 8 with 0 indicating no nail psoriasis and higher scores indicating worsening nail psoriasis.
| score on a scale | Placebo | Triamcinolone Acetonide 2.5 mg/mL | Triamcinolone Acetonide 5.0 mg/mL | Triamcinolone Acetonide 7.5 mg/mL | Triamcinolone Acetonide 10 mg/mL |
|---|---|---|---|---|---|
| Change From Baseline in Nail Psoriasis, as Measured by Nail Psoriasis Severity Index (NAPSI) | -0.96 (-1.81 to -0.11) | -3.96 (-4.64 to -3.27) | -2.96 (-3.62 to -2.31) | -3.53 (-4.2 to -2.85) | -3.93 (-4.62 to -3.24) |
The NPQ10 comprises 10 questions gauging the impact of nail psoriasis on daily activities. Each response is scored from 0 to 2, resulting in a total score between 0 and 20, where higher values indicate a more significant impact. The final scores are converted to percentages, reflecting the proportion of questions answered by the patient. The obtained score correlates proportionally with the level of functional difficulty experienced, with 0% indicating no impairment and 100% indicating the worst possible impairment.
| percentage of NPQ10 score | All Groups |
|---|---|
| Change From Baseline in Nail Psoriasis Qualify of Life, as Measured by Development and Validation of Nail Psoriasis Quality of Life Scale (NPQ10) | 4.5 (0 to 15) |
Adverse events will only include those that are determined to be related to the study drug.
| Participants | Triamcinolone Acetonide 2.5 mg/mL | Triamcinolone Acetonide 5.0 mg/mL | Triamcinolone Acetonide 7.5 mg/mL | Triamcinolone Acetonide 10 mg/mL | Placebo |
|---|---|---|---|---|---|
| Number of Participants With at Least One Adverse Event | 3 | 4 | 7 | 8 | 0 |
Collected over 24 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Triamcinolone Acetonide 2.5 mg/mL | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Triamcinolone Acetonide 5.0 mg/mL | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Triamcinolone Acetonide 7.5 mg/mL | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Triamcinolone Acetonide 10 mg/mL | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Event | Placebo | Triamcinolone Acetonide 2.5 mg/mL | Triamcinolone Acetonide 5.0 mg/mL | Triamcinolone Acetonide 7.5 mg/mL | Triamcinolone Acetonide 10 mg/mL |
|---|---|---|---|---|---|
| Cuticle retractionSkin and subcutaneous tissue disorders | 0/10 | 1/10 | 3/10 | 4/10 | 4/10 |
| OnychomadesisSkin and subcutaneous tissue disorders | 0/10 | 2/10 | 0/10 | 2/10 | 1/10 |
| ErythronychiaSkin and subcutaneous tissue disorders | 0/10 | 1/10 | 1/10 | 1/10 | 2/10 |
| Subungual hematomaSkin and subcutaneous tissue disorders | 0/10 | 1/10 | 1/10 | 1/10 | 0/10 |
| Longitudinal grooveSkin and subcutaneous tissue disorders | 0/10 | 0/10 | 0/10 | 1/10 | 0/10 |
| Beau's line(s)Skin and subcutaneous tissue disorders | 0/10 | 1/10 | 1/10 | 1/10 | 1/10 |
| Nail plate splitSkin and subcutaneous tissue disorders | 0/10 | 0/10 | 0/10 | 0/10 | 1/10 |
| Nail plate concavitySkin and subcutaneous tissue disorders | 0/10 | 0/10 | 0/10 | 0/10 | 1/10 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 51 ± 13 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 7 |
| Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 10 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 9 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | All Participants |
|---|---|
| United States | 11 |
| Nail Psoriasis Qualify of Life, as Measured by Development and Validation of Nail Psoriasis Quality(percentage of NPQ10 score) | All Participants |
|---|---|
| Mean | 7 (0 to 30) |
| Nail Psoriasis, as Measured by Nail Psoriasis Severity Index (NAPSI)(score on a scale) | All Participants |
|---|---|
| Triamcinolone acetonide 2.5 mg/mL | 5.3 (3 to 8) |
| Triamcinolone acetonide 5.0 mg/mL | 4.76 (3 to 7) |
| Triamcinolone acetonide 7.5 mg/mL | 4.75 (3 to 7) |
| Triamcinolone acetonide 10 mg/mL | 5.0 (3 to 8) |
| Placebo | 4.7 (3 to 6) |
| Total | 4.9 (3 to 8) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2020 to primary completion in Mar 2023, 36 months.
Results were first posted in Mar 2024, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triamcinolone Acetonide
Nail Diseases
Weill Medical College of Cornell University →